eli lilly Archives

Investor infographic illustrating Eli Lilly and Company (NYSE: LLY) investing up to $2.875 billion to acquire Merida Biosciences, linking Lilly’s headquarters and cash investment to Merida’s antibody-engineering candidates, precision immunology research, and projected future revenue growth.

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

by John F. Heerdink, Jr. September 1, 2026 219Views 0Likes

Eli Lilly and Company (NYSE: LLY) is making a confident and distinctly forward-looking move beyond its blockbuster obesity and diabetes franchises. Its agreement to acquire privately held Merida Biosciences for up to $2.875 billion in cash is a bullish vote for precision immunology:…

Alt text: Illustration of OpenAI’s $1 billion AI monetization opportunity, featuring AI-powered advertising dashboards, robots, digital healthcare consultations, data centers, drones, financial charts and connected technology infrastructure representing growth in artificial intelligence, telehealth and the broader market economy.

AI Monetization, Digital Care, and a Macro Backdrop Built for Builders? -( $AMWL $AMZN $GOOGL $META $MSFT $NVDA $OPAI.PVT $TTD )

by John F. Heerdink, Jr. August 31, 2026 204Views 0Likes

The market’s most investable theme today is not simply artificial intelligence, healthcare or macroeconomics in isolation. It is possibly the increasingly visible convergence of all three: businesses finding ways to monetize AI, healthcare platforms turning operational discipline into financial leverage, and policymakers…

Amylyx Ignites a New GLP-1 Investment Narrative as Clinical Data, Pharmacy Access and Diabetes Innovation Converge -( $AMLX $CVS $LLY $MODD $NVO )

by John F. Heerdink, Jr. August 18, 2026 358Views 0Likes

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has delivered the kind of Phase 3 result biotechnology investors wait patiently—and, on occasion, not so patiently—for. The company reported that avexitide reduced the composite rate of severe and clinically meaningful post-bariatric hypoglycemia events by 55% versus…

Not Your Grandfather’s Diabetes Kit: Eli Lilly’s Smart Ring Bet and Modular Medical’s Pivot Pump Rewire the Care Stack -( $LLY $MODD )

by John F. Heerdink, Jr. July 21, 2026 352Views 0Likes

Eli Lilly and Company’s (NYSE: LLY) recent equity investment in ŌURA Health and the Oura Ring ecosystem, paired with Modular Medical’s (NASDAQ: MODD) launch of its Pivot tubeless insulin patch pump, is giving Wall Street a preview of what next‑generation metabolic care…

Wall Street On A Good Trip: Lilly, CareDx, And Eupraxia Rewrite The Biotech Script -( $ATAI $CDNA $EPRX $LLY )

by John F. Heerdink, Jr. July 16, 2026 389Views 0Likes

Biotech’s latest plot twist has Wall Street grinning: a Big Pharma icon betting billions on psychedelics, a transplant diagnostics player finally getting its Medicare script approved, and a quietly ambitious drug-delivery innovator upgrading its cast of characters for the next act. Lilly’s…

From Molecules to Millions: How Eupraxia, Eli Lilly and Merck Navigate the FDA Maze -( $EPRX $LLY $MRK )

by John F. Heerdink, Jr. May 4, 2026 391Views 0Likes

The modern FDA approval maze is becoming less a straight corridor and more a high-speed roundabout—and investors riding with Eupraxia Pharmaceuticals (EPRX), Eli Lilly (LLY) and Merck (MRK) may find that’s exactly where outsized opportunity lives. From Wall Poster to Wall Street…

GLP-1s, Hairlines, and the Almost-Pumpers: Why Modular Medical May Be Ready for Its Close-Up -( $LLY $MODD )

by John F. Heerdink, Jr. May 2, 2026 365Views 0Likes

At this point, glucagon-like peptide-1 drugs, or GLP-1s, have become the market’s favorite lifestyle macro-theme, credited with trimming waistlines, lowering A1Cs, and supposedly reshaping everything from snack aisles to airplane seat designs. Yet in 2026, a new subplot is stealing some headlines:…

Eli Lilly’s Strategic Shopping Spree Signals a New Era in Biotech Consolidation -( $LLY $XBI $IBB )

by John F. Heerdink, Jr. April 29, 2026 347Views 0Likes

In a market where capital efficiency has become the new currency of credibility, Eli Lilly & Co. (LLY) appears to be writing a decidedly modern playbook for growth—one acquisition at a time. The Indianapolis-based pharmaceutical heavyweight has quietly assembled a portfolio of…

Eli Lilly Just Hired an Algorithm: Inside the $2.25 Billion AI Drug Whisperer Deal With Profluent -( $LLY $IBB $XBI )

by John F. Heerdink, Jr. April 29, 2026 522Views 0Likes

Eli Lilly’s (LLY) latest AI move reads less like a side project and more like a statement: the drugmaker is quietly trying to turn biology into software—and it just hired Profluent as one of its lead engineers. Lilly Bets Big On AI-Authored…

The Diabesity Gold Rush: GLP‑1 Giants and a Tiny Patch Pump Hunting for XXL Returns -( $AMGN GS $LLY $MODD $NVO )

by John F. Heerdink, Jr. April 8, 2026 480Views 0Likes

The global “diabesity” market is swelling into a once‑in‑a‑generation opportunity, and Eli Lilly, Novo Nordisk—and now a new class of device innovators like Modular Medical (NASDAQ: MODD)—are still lacing up their running shoes rather than sprinting for the finish line. For investors,…

Tag: eli lilly

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

AI Monetization, Digital Care, and a Macro Backdrop Built for Builders? -( $AMWL $AMZN $GOOGL $META $MSFT $NVDA $OPAI.PVT $TTD )

Amylyx Ignites a New GLP-1 Investment Narrative as Clinical Data, Pharmacy Access and Diabetes Innovation Converge -( $AMLX $CVS $LLY $MODD $NVO )

Not Your Grandfather’s Diabetes Kit: Eli Lilly’s Smart Ring Bet and Modular Medical’s Pivot Pump Rewire the Care Stack -( $LLY $MODD )

Wall Street On A Good Trip: Lilly, CareDx, And Eupraxia Rewrite The Biotech Script -( $ATAI $CDNA $EPRX $LLY )

From Molecules to Millions: How Eupraxia, Eli Lilly and Merck Navigate the FDA Maze -( $EPRX $LLY $MRK )

GLP-1s, Hairlines, and the Almost-Pumpers: Why Modular Medical May Be Ready for Its Close-Up -( $LLY $MODD )

Eli Lilly’s Strategic Shopping Spree Signals a New Era in Biotech Consolidation -( $LLY $XBI $IBB )

Eli Lilly Just Hired an Algorithm: Inside the $2.25 Billion AI Drug Whisperer Deal With Profluent -( $LLY $IBB $XBI )

The Diabesity Gold Rush: GLP‑1 Giants and a Tiny Patch Pump Hunting for XXL Returns -( $AMGN GS $LLY $MODD $NVO )

Your Guide To Staying Informed In The Markets